Financial Performance - The company achieved an annual revenue of CNY 1,098,568,103.53 in 2021, representing an 18.31% increase compared to the previous year[26]. - Net profit attributable to shareholders was CNY 244,137,406.56, reflecting a 7.20% growth year-over-year[26]. - The net profit after deducting non-recurring gains and losses reached CNY 184,868,648.42, marking a 21.05% increase from the prior year[26]. - The company's cash flow from operating activities was CNY 212,533,722.96, down 18.83% compared to 2020[26]. - The total assets of the company at the end of 2021 were CNY 2,168,280,813.81, a 6.87% increase from the end of 2020[26]. - The net assets attributable to shareholders reached CNY 1,800,452,116.65, reflecting a 5.31% increase year-over-year[26]. - The company achieved operating revenue of CNY 1,098,568,103.53, representing an 18.31% increase compared to the previous year[77]. - The sales revenue from swine vaccines increased by 47.23% year-on-year, while poultry vaccines and antibody sales grew by 7.04%[79]. - The gross margin for veterinary pharmaceuticals was 65.29%, an increase of 0.80 percentage points compared to the previous year[80]. - The company reported a total revenue of CNY 1.07 billion, with a gross margin of 65.29%, reflecting an 18.47% increase in revenue year-on-year[108]. Research and Development - Research and development expenses totaled CNY 85,572,300, accounting for 7.79% of total revenue[39]. - The company applied for 18 domestic and international invention patents during the year, with 38 patents granted[39]. - The company is advancing the development of genetically engineered subunit vaccines for major animal diseases, including African swine fever and foot-and-mouth disease, with clinical trial applications expected within the year[40]. - The company has established two major innovation platforms, including the Henan Provincial Veterinary Drug Technology Innovation Center, showcasing its leadership in technological innovation[41]. - The company has formed strategic partnerships with various research institutions to enhance its R&D capabilities[70]. - The company is focusing on innovative product development, particularly in the areas of next-generation genetic engineering vaccines and multi-valent vaccines, with a series of projects targeting strategic and market-demand products[109]. - Key research projects include the African Swine Fever subunit vaccine and the recombinant foot-and-mouth disease subunit vaccine, both currently in the preclinical research stage[112]. - The company has a robust pipeline of veterinary vaccines and pharmaceuticals, with ongoing projects aimed at addressing significant health challenges in livestock and pets[112]. Market and Product Development - The company has established a wholly-owned subsidiary focused on pet pharmaceuticals, with multiple products in development and clinical trial stages[49]. - The company is actively exploring marketing strategies that combine professional channel promotion and online marketing for its pet products[50]. - The company has made significant progress in the development of pet vaccines and chemical drugs, with several products receiving clinical trial approvals[49]. - The company aims to expand its market presence through innovative product offerings and strategic research initiatives[109]. - The company is committed to advancing its research capabilities to meet industry needs and enhance its competitive position[109]. - The company is focusing on expanding its market presence in the veterinary pharmaceutical industry, which is characterized by high concentration among large enterprises[103]. - The company has launched several new products, including a series of soluble powders and oral solutions, with specific registration numbers and expected release dates in 2026[121][122]. - The company is focusing on expanding its product line with new formulations such as injectable solutions and disinfectants, enhancing its market presence[126]. Corporate Governance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company’s financial report has been confirmed for its authenticity and completeness by its management team[4]. - The company maintains strict independence from its controlling shareholder, with no interference in decision-making or operations[164]. - The company has established a complete independent accounting system and financial management procedures[164]. - The company held 3 shareholder meetings during the reporting period, ensuring equal rights for all shareholders, especially minority shareholders[163]. - The board of directors consists of 9 members, including 3 independent directors, and held 11 meetings during the reporting period[163]. - The supervisory board convened 5 times during the reporting period, adhering to legal and regulatory requirements[164]. - The company has a clear three-year shareholder return plan for 2021-2023, which was also approved in the recent meetings[167]. Risk Management - The company has outlined various risks it may face in its production and operation processes, detailed in the report[8]. - The company faces risks from animal epidemics, regulatory changes, intensified market competition, product development challenges, and quality assurance issues[156][157][158][161]. Employee and Management Structure - The company has a total of 1,809 employees, with 976 in the parent company and 833 in major subsidiaries[198]. - The employee composition includes 838 production personnel, 509 sales personnel, 276 technical personnel, 41 financial personnel, and 145 administrative personnel[198]. - The company has optimized its salary structure in 2021, establishing a management salary system based on job sequences and improving the salary structure to enhance job security and highlight value contribution[199]. - The company has maintained a stable management structure with no changes in key positions during the reporting period[171]. Future Outlook - The company plans to raise up to 900 million RMB through a private placement to fund the construction of a high-pathogenic avian influenza inactivated vaccine production base and other projects, enhancing its industrial layout and production capacity[51]. - The company aims to complete the relocation and expansion of its production base by the end of 2023, which will help overcome current capacity bottlenecks and capitalize on market opportunities as high-pathogenic avian influenza vaccines exit government procurement by 2025[54]. - The company is considering strategic acquisitions to bolster its product portfolio, with a budget of $100 million allocated for potential deals[181]. - The company has set ambitious performance guidance for the upcoming fiscal year, aiming for a substantial increase in revenue and market share[123].

Financial Performance - The company's operating revenue for Q1 2022 was approximately ¥245.29 million, representing a decrease of 20.54% compared to the same period last year[5]. - The net profit attributable to shareholders was approximately ¥37.52 million, down 56.80% year-over-year[5]. - The net profit after deducting non-recurring gains and losses was approximately ¥34.83 million, a decrease of 59.22% compared to the previous year[5]. - The total comprehensive income for the first quarter of 2022 was CNY 37,523,007.05, down from CNY 86,849,170.37 in the first quarter of 2021, indicating a decrease of about 56.9%[32]. - The basic and diluted earnings per share for the first quarter of 2022 were both CNY 0.12, compared to CNY 0.28 in the first quarter of 2021, reflecting a decline of approximately 57.1%[32]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at approximately -¥8.50 million, an increase of 41.64% in outflow compared to the previous year[5]. - The net cash flow from operating activities for the first quarter of 2022 was negative CNY 8,500,573.99, an improvement from negative CNY 14,564,672.22 in the same period of 2021[37]. - Cash inflows from operating activities totaled CNY 204,732,960.36 in the first quarter of 2022, compared to CNY 233,335,334.97 in the first quarter of 2021, showing a decrease of about 12.3%[34]. - Cash outflows from operating activities amounted to CNY 213,233,534.35 in the first quarter of 2022, down from CNY 247,900,007.19 in the same period of 2021, indicating a decrease of approximately 14%[37]. - The net cash flow from investing activities was CNY 50,691,468.78 in the first quarter of 2022, compared to negative CNY 52,913,502.84 in the first quarter of 2021, showing a significant improvement[37]. - The cash and cash equivalents at the end of the first quarter of 2022 were CNY 243,614,922.68, an increase from CNY 172,778,796.83 at the end of the first quarter of 2021[37]. - The company received CNY 37,000,000.00 from borrowings in the first quarter of 2022, indicating active financing activities[37]. Assets and Liabilities - The total assets at the end of the reporting period were approximately ¥2.24 billion, an increase of 3.49% from the end of the previous year[7]. - Total assets reached CNY 2,243,983,991.38 as of March 31, 2022, compared to CNY 2,168,280,813.81 at the end of 2021, marking an increase of 3.5%[25]. - Total liabilities amounted to CNY 406,008,867.68 as of March 31, 2022, up from CNY 367,828,697.16 at the end of 2021, representing an increase of 10.3%[25]. - The company's retained earnings as of March 31, 2022, were CNY 1,017,448,491.22, an increase from CNY 979,925,484.17 at the end of 2021, showing a growth of 3.8%[25]. Revenue Breakdown - Revenue from pig vaccines decreased by 24.27% to approximately ¥83.49 million compared to the same period last year[8]. - Revenue from poultry vaccines and antibodies decreased by 10.85% to approximately ¥81.55 million year-over-year[8]. - Total operating revenue for Q1 2022 was CNY 245,291,876.69, a decrease of 20.5% compared to CNY 308,684,677.37 in Q1 2021[27]. - Total operating costs for Q1 2022 were CNY 199,560,937.12, down from CNY 205,374,036.34 in Q1 2021, reflecting a reduction of 2.0%[27]. - Research and development expenses for Q1 2022 amounted to CNY 15,802,688.91, a decrease of 20.5% from CNY 19,883,507.77 in Q1 2021[27]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 10,026, with the largest shareholder holding 33.47% of the shares[11].

Financial Performance - The company's operating revenue for the third quarter reached ¥241,787,918.71, representing a year-on-year increase of 7.14%[6] - Net profit attributable to shareholders was ¥67,027,689.59, showing a significant increase of 65.72% compared to the same period last year[6] - The net profit after deducting non-recurring gains and losses was ¥50,565,525.04, up 117.87% year-on-year[6] - The basic earnings per share for the quarter was ¥0.21, with a year-to-date figure of ¥0.73, reflecting a 43.14% increase[6] - Total operating revenue for the first three quarters of 2021 reached ¥821,018,803.18, a 27% increase compared to ¥647,434,110.71 in the same period of 2020[34] - Net profit for the first three quarters of 2021 was ¥230,629,480.23, representing a 44% increase from ¥160,471,917.44 in the same period of 2020[38] - Earnings per share for the first three quarters of 2021 were ¥0.73, compared to ¥0.51 in the same period of 2020[40] Revenue Breakdown - The revenue from swine vaccines for the first nine months was ¥291,837,752.90, marking a 70.69% increase compared to the same period last year[11] - The revenue from poultry vaccines and antibodies was ¥280,321,630.33, which is a 7.71% increase year-on-year[11] Assets and Liabilities - The total assets at the end of the reporting period were ¥2,120,119,014.46, a 4.50% increase from the end of the previous year[9] - The company's total liabilities were reported at CNY 853,364,267.26, compared to CNY 879,460,441.44 in the previous year[29] - The total liabilities as of the reporting date were ¥337,165,101.98, compared to ¥319,158,363.35 in the previous year[31] - Total equity attributable to shareholders reached ¥1,782,953,912.48, up from ¥1,709,645,282.25 in the previous year[31] Cash Flow - Operating cash inflows totaled $804,369,589.67, an increase from $664,903,082.43 in the previous period, reflecting a growth of approximately 21%[43] - Operating cash outflows amounted to $672,595,454.93, compared to $515,852,336.52 previously, indicating a rise of about 30%[43] - Net cash flow from operating activities was $131,774,134.74, down from $149,050,745.91, representing a decrease of around 12%[43] - Cash inflows from investment activities reached $677,652,291.92, a decline from $740,986,190.65, showing a decrease of approximately 8.5%[43] - The net cash flow from financing activities was negative at -$157,424,361.01, compared to -$191,840,359.27 previously[45] Shareholder Information - The company had a total of 15,339 common shareholders at the end of the reporting period[17] - The company repurchased 6,854,300 shares, representing 2.13% of the total share capital[24] - The company has not disclosed any significant changes in shareholder relationships or actions among the top shareholders[24] Other Financial Metrics - The weighted average return on equity for the quarter was 3.83%, an increase of 1.32 percentage points compared to the previous year[9] - The company's cash and cash equivalents were reported at CNY 250,419,311.84, slightly down from CNY 253,653,282.38 at the end of 2020[25] - Accounts receivable increased to CNY 273,480,554.03 from CNY 205,117,342.36 year-over-year, indicating a growth of approximately 33.3%[25] - Inventory levels rose significantly to CNY 202,962,860.91, compared to CNY 133,808,728.77 at the end of 2020, reflecting a growth of about 51.7%[25] - The company reported a significant increase in other receivables, which rose to CNY 5,844,690.35 from CNY 2,715,520.64[25] - Deferred income tax liabilities increased to ¥11,510,983.19 from ¥11,226,528.01 year-over-year[31] - Research and development expenses for the first three quarters of 2021 were ¥60,255,011.11, down from ¥86,470,942.29 in 2020[34] - The company reported a net exchange gain of ¥4,609,056.67, compared to a loss of ¥587,107.28 in the previous year[34]

Financial Performance - The company reported a significant increase in revenue for the first half of 2021, achieving a total of 500 million RMB, representing a growth of 25% compared to the same period last year[18]. - The company's operating revenue for the first half of 2021 was ¥579,230,884.47, representing a 37.34% increase compared to ¥421,758,167.79 in the same period last year[26]. - The net profit attributable to shareholders was ¥163,601,790.64, up 36.30% from ¥120,026,748.15 year-on-year[26]. - The net profit after deducting non-recurring gains and losses increased by 44.25%, reaching ¥147,465,861.99 compared to ¥102,230,868.70 in the previous year[26]. - The company achieved a revenue of CNY 579 million in the first half of 2021, representing a growth of 37.34% compared to the same period last year[50]. - The net profit attributable to the parent company was CNY 164 million, an increase of 36.30% year-on-year, while the net profit after deducting non-recurring gains and losses was CNY 147 million, up 44.25% year-on-year[50]. - The total comprehensive income for the period reached ¥163,601,790.64, up from ¥120,026,748.15 in the previous period, representing a growth of approximately 36.2%[139]. - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the first half of 2021, representing a 15% year-over-year growth[100]. Research and Development - The management highlighted the importance of technological advancements, with a 30% increase in R&D spending, totaling 150 million RMB for the current fiscal year[18]. - The company's R&D investment totaled CNY 39.57 million, accounting for 6.83% of revenue, supporting various R&D activities[51]. - The company is actively developing a bivalent three-component genetic engineering subunit vaccine for highly pathogenic avian influenza (H5+H7) and has submitted clinical trial applications for it[51]. - The company is collaborating with research institutes to advance the clinical research of a composite subunit vaccine for African swine fever[54]. - The company focuses on innovation, with gene-engineered vaccines and multi-valent vaccines gaining popularity among users[33]. - The company has established national-level R&D platforms, employing over 260 technical staff to drive product development[44]. - The company has formed a rapid and efficient product R&D system based on market demand and competitive analysis[36]. Market Expansion and Strategy - The company is actively pursuing market expansion strategies, targeting new regions in Southeast Asia, with an estimated investment of 50 million RMB for market entry[18]. - The company has initiated a strategic acquisition of a local competitor, expected to close by Q4 2021, which will enhance market capabilities[106]. - The company is expanding its market presence in Southeast Asia, targeting a 25% market share by 2023[104]. - The company plans to implement a new marketing strategy aimed at increasing brand awareness, with a budget allocation of 50 million RMB[100]. Operational Challenges and Risks - The company has identified potential risks in the supply chain, which could impact production capacity by up to 10% if not addressed promptly[18]. - The company faces significant operational risks due to potential outbreaks of animal diseases, which could drastically reduce the number of animals and impact business performance[69]. - Regulatory risks are increasing as government policies regarding veterinary drug development, production, and sales become more stringent, potentially delaying R&D progress and increasing costs[70]. - R&D risks are present due to the lengthy and complex process of developing and registering new veterinary drugs, which may lead to delays or failures[72]. Sustainability and Environmental Responsibility - The company remains committed to sustainability initiatives, allocating 20 million RMB towards environmental and social responsibility projects in 2021[18]. - The company was recognized as a key pollutant discharge unit by the Henan Provincial Ecological Environment Department, indicating its environmental responsibilities[81]. - The company achieved a wastewater treatment standard with COD emissions of 11.9038 tons/year and ammonia nitrogen emissions of 1.1687 tons/year[83]. - The company has implemented an emergency response plan for environmental incidents, which is regularly trained and rehearsed[88]. - The company has ensured that all construction projects comply with environmental impact assessment regulations[87]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 11,688[111]. - The largest shareholder, Zhang Xuke, held 107,619,672 shares, representing 33.47% of the total shares[111]. - The second-largest shareholder, Sun Jinzhu, held 29,915,348 shares, accounting for 9.31%[114]. - The top ten shareholders collectively held a significant portion of the company's shares, with the largest holding being 33.47%[111]. - The company did not report any changes in its share capital structure during the reporting period[111]. Financial Position and Assets - The company's total assets at the end of the reporting period were ¥2,060,963,273.62, a 1.59% increase from ¥2,028,803,645.60 at the end of the previous year[26]. - The company's cash and cash equivalents stood at RMB 147,277,834.81, down from RMB 253,653,282.38, representing a decrease of approximately 42%[124]. - Accounts receivable increased to RMB 319,151,031.08 from RMB 205,117,342.36, marking a significant rise of about 55.5%[124]. - The total liabilities reached RMB 345,037,050.73, compared to RMB 319,158,363.35 at the end of 2020, reflecting an increase of about 8.1%[126]. - The company's equity attributable to shareholders was RMB 1,715,926,222.89, slightly up from RMB 1,709,645,282.25, indicating a growth of approximately 0.4%[126].

证券代码：603566 证券简称：普莱柯 公告编号：2021-027 普莱柯生物工程股份有限公司 关于参加河南辖区上市公司 2021 年投资者网上集体接待日 活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 为进一步加强与投资者的互动交流，使广大投资者能更深入全面地了解普莱 柯生物工程股份有限公司（以下简称"公司"）情况，本公司将参加由河南证监 局与河南省上市公司协会、深圳市全景网络有限公司举办的 2021 年河南辖区上 市公司投资者网上集体接待日活动。现将有关事项公告如下： 公司定于 2021 年 6 月 8 日（周二）16：00-17：20 参加在全景网举办的"真 诚沟通 传递价值"河南辖区上市公司 2021 年投资者网上集体接待日活动，本次 活动将采用网络远程的方式举行，投资者可登录"全景•路演天下" （http://rs.p5w.net）参与本次互动交流。 出席本次网上集体接待日活动的人员为董事会秘书赵锐先生。 欢迎广大投资者积极参与。 特此公告 普莱柯生物工程股份有限公司 董 事 会 2021 年 6 ...

Financial Performance - Operating revenue for the period was CNY 308,684,677.37, representing a year-on-year growth of 59.81%[12] - Net profit attributable to shareholders was CNY 86,849,170.37, up 46.21% from the same period last year[12] - Basic earnings per share rose by 55.56% to CNY 0.28[12] - The company's operating revenue for Q1 2021 was CNY 159,481,775.01, an increase from CNY 105,745,260.14 in Q1 2020, representing a growth of approximately 50.8%[50] - The net profit attributable to shareholders for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, reflecting an increase of about 46.2%[49] - The total profit for Q1 2021 was CNY 101,678,458.31, compared to CNY 67,040,371.34 in Q1 2020, representing an increase of approximately 51.6%[49] - The total comprehensive income for Q1 2021 was CNY 86,849,170.37, compared to CNY 59,400,827.59 in Q1 2020, indicating an increase of about 46.2%[50] Revenue Breakdown - Revenue from pig vaccines surged by 191.13% to CNY 110,235,441.30 compared to the previous year[15] - Revenue from chemical drugs increased by 63.22% to CNY 100,298,781.19 year-on-year[15] - Operating revenue rose by 59.81% to ¥308,684,677.37 compared to ¥193,156,705.35, primarily driven by sales of veterinary biological products and chemical drugs[21] Cash Flow - The net cash flow from operating activities was negative at CNY -14,564,672.22, a decline of 640.38% compared to the previous year[12] - Operating cash inflow totaled CNY 233,335,334.97, an increase from CNY 164,741,820.69 year-over-year[58] - Operating cash outflow amounted to CNY 247,900,007.19, compared to CNY 162,046,556.19 in the previous year[58] - Cash flow from investing activities showed a net outflow of CNY -52,913,502.84, contrasting with a net inflow of CNY 176,152,112.24 in the previous year[60] - Cash flow from financing activities resulted in a net outflow of CNY -100,004,090.87, consistent with the previous year's outflow[60] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 2,117,453,881.78, an increase of 4.37% compared to the end of the previous year[12] - Non-current assets totaled ¥1,167,747,772.84, up from ¥1,149,343,204.16, indicating a growth in long-term investments[30] - Total liabilities amounted to ¥320,959,429.16, slightly increasing from ¥319,158,363.35, reflecting stable financial leverage[33] - The company's total liabilities decreased to ¥207,189,424.84 from ¥213,673,007.42, a reduction of approximately 3%[41] Shareholder Information - The company reported a total of 12,807 shareholders at the end of the reporting period[15] - The top shareholder, Zhang Xuke, holds 33.47% of the shares, totaling 107,619,672 shares[15] Expenses - Operating costs increased by 42.00% to ¥97,889,843.70 from ¥68,937,426.28, reflecting higher sales volumes[21] - Sales expenses surged by 102.17% to ¥66,530,190.77 from ¥32,907,838.56, attributed to increased marketing expenses[21] - Research and development expenses in Q1 2021 amounted to ¥19,883,507.77, compared to ¥16,846,927.91 in Q1 2020, indicating a 17.9% increase[44] - Research and development expenses for Q1 2021 were CNY 12,468,104.83, slightly up from CNY 11,595,555.03 in Q1 2020, showing a year-over-year increase of about 7.5%[50] Other Income and Losses - Other income decreased by 80.17% to ¥990,002.15 from ¥4,991,297.68, primarily due to reduced government subsidies related to daily operations[21] - Investment income fell by 57.43% to ¥875,665.33 from ¥2,057,077.35, mainly due to decreased returns from associated companies[21] - The company incurred a credit impairment loss of CNY 1,909,521.53 in Q1 2021, compared to CNY 2,095,828.79 in Q1 2020, reflecting a decrease of approximately 8.8%[49] - The company's other income for Q1 2021 was CNY 990,002.15, significantly lower than CNY 4,991,297.68 in Q1 2020, indicating a decline of about 80.2%[49] Inventory and Accounts - Accounts receivable increased by 42.57% to ¥292,426,520.56 from ¥205,117,342.36 due to increased revenue[21] - Inventory and contract assets rose to ¥91,418,376.91 from ¥71,772,524.63, marking a 27.4% increase[41] - The company reported a decrease in accounts payable from ¥22,167,632.28 in Q1 2020 to ¥20,581,035.94 in Q1 2021, a decline of 7.2%[41]

Financial Performance - The company's operating revenue for 2020 was CNY 928,511,813.36, representing a 40.01% increase compared to CNY 663,194,736.53 in 2019[26]. - The net profit attributable to shareholders for 2020 was CNY 227,744,103.42, which is an increase of 108.47% from CNY 109,246,252.70 in 2019[26]. - The net cash flow from operating activities for 2020 was CNY 261,831,612.30, up 86.89% from CNY 140,103,014.96 in 2019[26]. - The basic earnings per share for 2020 was CNY 0.72, a 111.76% increase from CNY 0.34 in 2019[26]. - The total assets at the end of 2020 were CNY 2,028,803,645.60, reflecting a 6.47% increase from CNY 1,905,460,495.00 at the end of 2019[26]. - The company reported a net asset attributable to shareholders of CNY 1,709,645,282.25 at the end of 2020, which is a 3.11% increase from CNY 1,658,042,540.88 at the end of 2019[26]. - The company achieved a weighted average return on equity of 13.86% in 2020, an increase of 7.18 percentage points from 6.68% in 2019[26]. - The company reported a total revenue of 373.77 million RMB for the year 2020[168]. - The company achieved a total R&D expenditure of ¥114.84 million, accounting for 12.37% of total revenue[81]. - The company reported a significant increase in sales for the poultry vaccine segment, with a revenue growth of 323.37% for the five-in-one inactivated vaccine[113]. Dividends and Shareholder Returns - The company plans to distribute cash dividends of RMB 5 per 10 shares, totaling an estimated cash dividend of RMB 157.32 million (including tax) based on the adjusted total share capital as of December 31, 2020[6]. - The company distributed a cash dividend of 2 RMB per share, totaling 63.18264 million RMB, based on a shareholder base of 315,913,200 shares[142]. - The company reported a net profit of 227,744,103.42 RMB for 2020, with a cash dividend amounting to 133,522,943.54 RMB, which is 58.63% of the total[143]. - The company’s cash dividend distribution has shown a consistent increase over the past three years, reflecting a commitment to returning value to shareholders[143]. - The company has not proposed a cash profit distribution plan for the reporting period despite having positive distributable profits[143]. - The company repurchased shares for a total cash payment of 134 million yuan, achieving good shareholder returns[198]. Governance and Compliance - The company has received a standard unqualified audit report from the accounting firm, ensuring the accuracy and completeness of the financial report[5]. - The company has confirmed that all board members attended the board meeting, ensuring governance and oversight[5]. - The company has not violated decision-making procedures in providing guarantees, maintaining compliance with regulations[8]. - The company has not faced any situations where more than half of the directors could not guarantee the authenticity and completeness of the annual report[8]. - The company is committed to ensuring the financial report's authenticity, accuracy, and completeness, as stated by its responsible personnel[5]. - The actual controller and major shareholders have committed to not engaging in any business that competes with the company during their tenure[144]. - The company’s major shareholders are subject to a lock-up period of two years post-IPO, with specific conditions for share reduction[144]. - The company has made commitments to ensure the accuracy and completeness of its IPO prospectus, with legal responsibilities for any misrepresentation[144]. Research and Development - The company’s R&D investment has consistently exceeded 10% of its revenue over the past three years, leading to the acquisition of 55 new veterinary drug certificates and 496 invention patent applications[45]. - The company has developed a range of innovative vaccines, including gene-engineered and multi-valent vaccines, which are crucial for disease control in livestock[35]. - The company is actively developing a vaccine for African swine fever, with clinical trials already completed in multiple locations[56]. - The company is focusing on expanding its product line with new veterinary drugs and vaccines[106]. - The company has made significant advancements in R&D for new veterinary products, including a new inactivated vaccine for avian influenza[106]. - The company has received clinical trial approval for a canine distemper and parvovirus combined live vaccine[109]. - The company is developing a vaccine for Seneca Valley virus, currently in the new veterinary drug registration phase[97]. - The company is conducting clinical trials for a live vaccine against pseudorabies in pigs[97]. Market and Sales Strategy - The company operates in the veterinary biopharmaceuticals sector, focusing on the R&D, production, and sales of veterinary biological products and chemical drugs, with over 50 biological products and more than 200 chemical drugs available[35]. - The company utilizes a sales model that includes distribution, direct sales, and government procurement to effectively reach various customer segments[41]. - The company has established a strong sales network with 4,152 terminal distributors and 3,179 cooperative large-scale farms by the end of the reporting period[61]. - The company’s marketing strategy focuses on large group customer development and optimizing regional agency management, leading to significant sales growth[60]. - The company is focusing on international market expansion and high-end brand cultivation, aiming for comprehensive output in products, technology, and capital[126]. - The company plans to implement a comprehensive marketing management system, emphasizing standardized, process-oriented, and digitalized marketing strategies to improve efficiency[130]. Risks and Challenges - The company has outlined various risks faced in its production and operations, which are detailed in the report[8]. - The company faces risks related to animal disease outbreaks, regulatory changes, intensified market competition, product development challenges, and product quality assurance[133][136][137][138][139]. - The implementation of the new veterinary drug GMP has raised industry entry barriers and accelerated the exit of outdated production capacity, leading to increased industry concentration[125]. - The company emphasizes the importance of compliance and innovation in response to stringent regulatory policies affecting the veterinary drug industry[136]. Financial Management and Investments - The company has entrusted cash asset management with a total of 622.2 million RMB in principal for guaranteed products[180]. - Non-guaranteed financial products amounted to 465 million RMB, with an outstanding balance of 220 million RMB[180]. - The company has a total of 1,200,000 RMB in floating return wealth management at Agricultural Bank, with an actual return of 3,110 RMB[189]. - The company has a future plan for wealth management, although specific details were not disclosed[183]. - The company has recovered 99,020 RMB from a 5,000,000 RMB investment in floating return wealth management at CITIC Bank[186].

Financial Performance - Net profit attributable to shareholders was CNY 160,471,917.44, representing an increase of 68.79% year-on-year[17]. - Operating income for the period was CNY 639,601,996.04, reflecting a growth of 38.28% compared to the same period last year[19]. - Cash flow from operating activities reached CNY 149,050,745.91, up 109.41% year-on-year[17]. - The revenue from pig vaccines was CNY 170,972,778.43, an increase of 128.71% compared to the previous year[19]. - The revenue from poultry vaccines and antibodies was CNY 260,249,801.64, showing a growth of 23.18% year-on-year[19]. - The company reported a net profit excluding non-recurring gains and losses of CNY 125,439,659.38, up 82.73% year-on-year[17]. - Basic earnings per share rose to CNY 0.51, a 70.00% increase from the previous year[17]. - The company's net profit for the first three quarters of 2020 was ¥647,434,110.71, compared to ¥470,939,716.89 in the same period of 2019, reflecting a growth of approximately 37%[45]. - The net profit attributable to shareholders for Q3 2020 was ¥40.45 million, up 35% from ¥29.99 million in Q3 2019[52]. - The total profit for Q3 2020 was ¥48.32 million, compared to ¥34.18 million in Q3 2019, reflecting a growth of 41%[52]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,881,525,302.79, a decrease of 1.26% compared to the end of the previous year[17]. - Total liabilities increased to ¥254,809,545.03 from ¥247,417,954.12[37]. - Owner's equity remained stable at ¥321,496,000.00[37]. - Accounts receivable increased by 54.68% to ¥198,858,360.24 due to higher operating income[27]. - Other receivables decreased by 86.12% to ¥4,538,165.91 primarily from the recovery of loans by a subsidiary[27]. - Construction in progress rose by 56.66% to ¥49,243,116.46 due to increased investment in construction projects[27]. - Other non-current assets increased by 107.17% to ¥70,325,773.36 mainly from prepayments for engineering equipment[27]. - Total assets as of September 30, 2020, amounted to ¥1,658,435,872.24, a decrease from ¥1,768,603,489.29 at the end of 2019[43]. - The total liabilities as of September 30, 2020, were ¥162,767,740.09, down from ¥168,847,352.59 at the end of 2019[45]. - The company reported a total equity attributable to shareholders of ¥1,495,668,132.15, down from ¥1,599,756,136.70 at the end of 2019[45]. Cash Flow - Cash received from operating activities increased by 108.60% to ¥74,322,390.02 due to loan recoveries and increased government subsidies[30]. - Cash inflow from operating activities totaled CNY 664,903,082.43, an increase from CNY 488,878,915.40 in the same period last year, marking a growth of about 36%[59]. - Cash outflow from operating activities was CNY 515,852,336.52, compared to CNY 417,700,979.10 in the previous year, representing an increase of approximately 23.5%[63]. - The net cash flow from operating activities was CNY 149,050,745.91, significantly higher than CNY 71,177,936.30 in the same quarter of 2019, indicating an increase of about 109%[63]. - Cash flow from investment activities showed a net outflow of CNY 39,395,366.07, an improvement from a net outflow of CNY 169,443,698.40 in the previous year[63]. Operational Metrics - The weighted average return on net assets increased by 4.01 percentage points to 9.84%[17]. - Total operating revenue for Q3 2020 reached ¥225,675,942.92, a significant increase from ¥151,357,226.59 in Q3 2019, representing a growth of approximately 49%[45]. - Total operating costs for Q3 2020 were ¥198,613,854.26, up from ¥121,728,772.78 in Q3 2019, indicating an increase of about 63%[45]. - The company's operating revenue for Q3 2020 was approximately ¥117.96 million, a 39% increase from ¥84.85 million in Q3 2019[55]. - The company's basic earnings per share for Q3 2020 was ¥0.51, an increase from ¥0.30 in Q3 2019[54]. Research and Development - Research and development expenses in Q3 2020 reached ¥37.20 million, significantly higher than ¥10.62 million in Q3 2019, indicating a focus on innovation[55]. Financial Management - The financial expenses for Q3 2020 were reduced to -¥105.83 thousand from -¥1.59 million in Q3 2019, showing improved financial management[55]. - The company noted a significant adjustment in the financial statements due to the implementation of new accounting standards[77].

Financial Performance - The company reported a significant increase in revenue for the first half of 2020, with a year-on-year growth of 15%[2] - The company's operating revenue for the first half of 2020 reached ¥421,758,167.79, representing a year-on-year increase of 31.97%[21] - Net profit attributable to shareholders was ¥120,026,748.15, an increase of 84.44% compared to the same period last year[21] - The net profit after deducting non-recurring gains and losses increased by 129.14%, amounting to ¥102,230,868.70[21] - The total operating income for the reporting period was 319,582,490.30, an increase of 31.97% compared to the same period last year[54] - The total profit for the first half of 2020 was 138,256,504.54, compared to 72,072,701.66 in the first half of 2019, representing an increase of approximately 92.0%[151] - The company reported a financial income of -1,913,499.29 for the first half of 2020, an improvement compared to -3,124,403.86 in the first half of 2019[148] - The company achieved a gross profit margin of approximately 68.7% in the first half of 2020, compared to 67.4% in the same period of 2019[152] Research and Development - The company has allocated 15% of its annual budget towards new technology research and development initiatives[2] - The company invested 41.28 million RMB in R&D, accounting for 9.92% of its main business revenue[47] - The company has established three national-level R&D platforms to enhance its innovation capabilities in the veterinary medicine sector[31] - The company is actively developing multi-valent poultry vaccine projects to enhance product technology barriers and upgrade poultry vaccine products[48] - The company has completed the upgrade of the high pathogenic avian influenza vaccine production workshop and is preparing for GMP acceptance[53] Market Expansion and Product Development - User data indicates a growing customer base, with an increase of 20% in active users compared to the previous year[2] - The company has set a future outlook with a revenue target of 1 billion yuan for the next fiscal year, representing a 25% increase from the current year[2] - New product development includes the launch of a novel vaccine, which is expected to capture 30% of the market share within the first year of release[2] - The company is expanding its market presence, targeting an additional 10 provinces in the next 12 months[2] - The company achieved sales revenue of 0.97 billion, 1.81 billion, and 1.27 billion for pig vaccines, poultry vaccines and antibodies, and chemical drugs respectively, representing year-on-year growth of 79.45%, 26.02%, and 21.14%[49] Financial Position and Cash Flow - The company's cash and cash equivalents at the end of the reporting period were 260,896,521.34, a 52.48% increase from 171,105,020.19 in the previous year[59] - The company’s cash flow from operating activities was 2,386,018.47, showing a significant increase due to higher cash received from sales of goods and services[56] - The company’s cash flow from operating activities generated a net amount of RMB 67.40 million, significantly up from RMB 2.39 million in the first half of 2019[160] - The total cash inflow from operating activities of RMB 257,836,505.27, up from RMB 187,827,282.02 in the first half of 2019, marking a growth of approximately 37.2%[164] Risks and Challenges - The management highlighted potential risks, including regulatory changes that could impact product approvals and market access[2] - The company is facing external risks including policy changes, animal epidemic risks, and market competition, which could impact operational goals[72] - Internal risks include product development and quality risks, which may delay or hinder the progress of new product launches[78][79] Shareholder and Governance Matters - The company reported a commitment to not engage in any business activities that compete with its existing operations during the tenure of its controlling shareholder, Zhang Xuke[86] - The controlling shareholder has committed to not invest in or operate any similar businesses that would compete with the company, ensuring no conflicts of interest[86] - The company has established a framework for compensating investors in case of losses due to non-fulfillment of commitments by its executives[88] - The company has not reported any breaches of commitments during the reporting period, indicating strict compliance with its obligations[86] Environmental and Compliance Issues - The company was listed as a key pollutant discharge unit by the Jiangsu Provincial Ecological Environment Department[109] - Wastewater treatment facilities are fully equipped and operating stably, with treated wastewater meeting discharge standards[112] - The company has implemented an emergency response plan for environmental incidents and conducts annual training[114] Shareholder Structure and Equity - A total of 5,957,000 shares were repurchased, accounting for 1.85% of the company's total share capital, with a total expenditure of approximately RMB 110.27 million[121] - The total number of common shareholders at the end of the reporting period was 11,085[124] - The top shareholder, Zhang Xuke, holds 107,619,672 shares, representing 33.47% of the total shares[124] - The second-largest shareholder, Sun Jinzhu, holds 45,947,048 shares, accounting for 14.29%[124]

B ulike 股票代码：603566 公司简称：普 莱 柯 普莱柯生物工程股份有限公司 2020年第一季度报告 创 / / / / 未 / 来 2020 年第一季度报告 一、 二、 11Í 四、 目录 | --- | |----------------| | | | 重要提示 . | | 公司基本情况 . | | 重要事项 . | | 附录 . | 2 / 18 2020 年第一季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人张许科、主管会计工作负责人胡伟及会计机构负责人（会计主管人员）裴莲凤保 证季度报告中财务报表的真实、准确、完整。 1.4 本公司第一季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | --- | --- | --- | --- | |------------------------------------------------|---------- ...